Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Growth in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 74,800 shares, an increase of 8.6% from the March 15th total of 68,900 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average trading volume of 768,800 shares, the short-interest ratio is presently 0.1 days.

Achilles Therapeutics Trading Down 2.4 %

Achilles Therapeutics stock opened at $0.83 on Tuesday. The stock has a market cap of $33.10 million, a P/E ratio of -0.48 and a beta of 1.09. The company has a fifty day simple moving average of $1.14 and a 200-day simple moving average of $0.96. Achilles Therapeutics has a 12-month low of $0.74 and a 12-month high of $1.76.

Institutional Investors Weigh In On Achilles Therapeutics

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new stake in Achilles Therapeutics in the fourth quarter valued at $28,000. Bank of America Corp DE raised its holdings in shares of Achilles Therapeutics by 130.8% in the first quarter. Bank of America Corp DE now owns 10,450 shares of the company’s stock valued at $31,000 after buying an additional 5,922 shares during the last quarter. Balyasny Asset Management LLC acquired a new position in shares of Achilles Therapeutics during the third quarter worth about $39,000. Jane Street Group LLC acquired a new position in Achilles Therapeutics during the fourth quarter worth about $41,000. Finally, Sei Investments Co. acquired a new stake in shares of Achilles Therapeutics in the second quarter valued at approximately $59,000. 56.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ACHL has been the subject of several research reports. Chardan Capital dropped their price target on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, April 5th. Piper Sandler restated a “neutral” rating and issued a $2.00 price target (down previously from $8.00) on shares of Achilles Therapeutics in a research note on Friday, April 5th.

Achilles Therapeutics Company Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.